share_log

Allarity Therapeutics | DEFR14A: Definitive proxy statement in connection with contested solicitations

Allarity Therapeutics | DEFR14A: Definitive proxy statement in connection with contested solicitations

Allarity Therapeutics | DEFR14A：修正后委托征集材料
美股SEC公告 ·  08/20 12:52

Moomoo AI 已提取核心信息

Allarity Therapeutics, Inc. announced that it will be holding its 2024 Annual Meeting of Stockholders on September 3, 2024, at 10:00 a.m. Eastern Time. The meeting will be conducted virtually via live audio webcast. The agenda includes several key proposals, such as the election of two Class II directors, Gerald W. McLaughlin and Laura E. Benjamin, the ratification of Wolf & Company, P.C. as the independent auditor for the fiscal year ending December 31, 2024, and amendments to the company's Certificate of Incorporation to decrease authorized shares and common stock. Additionally, proposals to effect a reverse stock split, approve amendments to the 2021 Equity Incentive Plan, limit the liability of certain officers, and adjourn the meeting if necessary to solicit additional proxies are also on the docket. The board recommends voting FOR all the proposals. The meeting will also address the transaction of other business that may properly come before the Annual Meeting or any continuation, postponement, or adjournment thereof.
Allarity Therapeutics, Inc. announced that it will be holding its 2024 Annual Meeting of Stockholders on September 3, 2024, at 10:00 a.m. Eastern Time. The meeting will be conducted virtually via live audio webcast. The agenda includes several key proposals, such as the election of two Class II directors, Gerald W. McLaughlin and Laura E. Benjamin, the ratification of Wolf & Company, P.C. as the independent auditor for the fiscal year ending December 31, 2024, and amendments to the company's Certificate of Incorporation to decrease authorized shares and common stock. Additionally, proposals to effect a reverse stock split, approve amendments to the 2021 Equity Incentive Plan, limit the liability of certain officers, and adjourn the meeting if necessary to solicit additional proxies are also on the docket. The board recommends voting FOR all the proposals. The meeting will also address the transaction of other business that may properly come before the Annual Meeting or any continuation, postponement, or adjournment thereof.
Allarity Therapeutics, Inc.宣布将于2024年9月3日美国东部时间上午10:00举行2024年股东年度会议。会议将通过实时音频网络广播进行。议程包括数个关键提案，例如选举两位第二类董事，Gerald W. McLaughlin和Laura E. Benjamin，批准Wolf & Company，P.C.作为截至2024年12月31日财年的独立审计师，以及修改公司的公司章程以减少授权股份和普通股。此外，提议实施股票拆分，批准修改2021年股权激励计划，限制某些高管的责任，并如果必要委托代理人进行补充授权的大会，同样也在议程之中。董事会建议所有提案都应投票支持。该会议还将处理任何妥善出席年度会议的其他业务，无论是续期、延期或中止会议。
Allarity Therapeutics, Inc.宣布将于2024年9月3日美国东部时间上午10:00举行2024年股东年度会议。会议将通过实时音频网络广播进行。议程包括数个关键提案，例如选举两位第二类董事，Gerald W. McLaughlin和Laura E. Benjamin，批准Wolf & Company，P.C.作为截至2024年12月31日财年的独立审计师，以及修改公司的公司章程以减少授权股份和普通股。此外，提议实施股票拆分，批准修改2021年股权激励计划，限制某些高管的责任，并如果必要委托代理人进行补充授权的大会，同样也在议程之中。董事会建议所有提案都应投票支持。该会议还将处理任何妥善出席年度会议的其他业务，无论是续期、延期或中止会议。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间